Your search history is turned on.
Date: April 25, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
NervGen Engages Russo Partners LLC to Provide Public Relations Services Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC ("Russo Partn...
Date: April 17, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024 CA$23 million bought deal financing completed in March 2024 provides expected cash runway through Q3 2025 Fast Track designation granted by U.S. Food and Drug Administration (FDA) for NVG-291 in spinal cord injury ...
Date: April 17, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, ADAMS, William, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonabl...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
_ Unofficial consolidation for financial years beginning on or after January 1, 2011 Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, William Adams, Chief Financial Officer of NervGen Pharma Corp., certify the following: 1. Review: I have reviewed the annual financial statements and annual ...
_ Unofficial consolidation for financial years beginning on or after January 1, 2011 Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, Michael Kelly, President & Chief Executive Officer of NervGen Pharma Corp., certify the following: 1. Review: I have reviewed the annual financial statements...
1 Managements Discussion and Analysis of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars) For the years ended December 31, 2023 and 2022 Effective Date: April 16, 2024 NERVGEN PHARMA CORP. 2023 ANNUAL MD&A 1 MANAGEMENTS DISCUSSION AND ANAL...
Audit of general purpose financial statements of a listed entity Consolidated financial statements of NERVGEN PHARMA CORP. (Expressed in Canadian Dollars) For the years ended December 31, 2023 and 2022 KPMG LLP PO Box 10426 777 Dunsmuir Street Vancouver BC V7Y 1K3 Canada Telephone (...
Date: April 1, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
Microsoft Word - 1390-6301-5691-v4-NervGen - MCR (Bought Deal).docx Form 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Reporting Issuer NervGen Pharma Corp. (NervGen or the Company) 112-970 Burrard Street Unit 1290 Vancouver, BC V6Z 2R4 Item 2. Date of Material Changes March 21, 2024 and March 28, 2024 Item 3. News Releases Ne...
Date: March 28, 2024 Jurisdictions: Alberta, British Columbia, Nova Scotia, Ontario
Microsoft Word - NervGen - Warrant Indenture (2024 Prospectus Supplement) 1395-8572-1099 v.7.docx NERVGEN PHARMA CORP. as the Corporation and COMPUTERSHARE TRUST COMPANY OF CANADA as the Warrant Agent WARRANT INDENTURE Providing for the Issue of Warrants Dated as of March 28, 2024 TABLE OF CONTENTS Page No. ...